Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Pišlar, Anja" wg kryterium: Autor


Wyświetlanie 1-9 z 9
Tytuł:
Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties
Autorzy:
Malawska, Barbara
Bajda, Marek
Gobec, Stanislav
Kos, Janko
Brus, Boris
Lewiński, Krzysztof
Pišlar, Anja
Szałaj, Natalia
Skrok, Mirosław
Kurpiewska, Katarzyna
Opis:
The presented study describes the synthesis, pharmacological evaluation (AChE and BuChE inhibition, beta amyloid anti-aggregation effect and neuroprotective effect), molecular modeling and crystallographic studies of a novel series of isoindoline-1,3-dione derivatives. The target compounds were designed as dual binding site acetylcholinesterase inhibitors with an arylalkylamine moiety binding at the catalytic site of the enzyme and connected via an alkyl chain to a heterocyclic fragment, capable of binding at the peripheral anionic site of AChE. Among these molecules, compound 15b was found to be the most potent and selective AChE inhibitor (IC50EeAChE = 0.034 μM). Moreover, compound 13b in addition to AChE inhibition (IC50 EeAChE = 0.219 μM) possesses additional properties, such as the ability to inhibit Aβ aggregation (65.96% at 10 μM) and a neuroprotective effect against Aβ toxicity at 1 and 3 μM. Compound 13b emerges as a promising multi-target ligand for the further development of the therapy for age-related neurodegenerative disorders.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
Development of an in-vivo active reversible butyrylcholinesterase inhibitor
Autorzy:
Brus, Boris
Brazzolotto, Xavier
Sałat, Kinga
Malawska, Barbara
Filipek, Barbara
Nachon, Florian
Trontelj, Jurij
Perše, Martina
Kos, Janko
Gobec, Stanislav
Košak, Urban
Mlinarič Raščan, Irena
Podkowa, Adrian
Coquelle, Nicolas
Šink, Roman
Šlenc, Jasna
Colletier, Jacques-Philippe
Tratnjek, Larisa
Knez, Damijan
Pišlar, Anja
Gobec, Martina
Živin, Marko
Stojan, Jure
Žakelj, Simon
Więckowska, Anna
Opis:
Alzheimer’s disease (AD) is characterized by severe basal forebrain cholinergic deficit, which results in progressive and chronic deterioration of memory and cognitive functions. Similar to acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic neurotransmission. Its enzymatic activity increases with the disease progression, thus classifying BChE as a viable therapeutic target in advanced AD. Potent, selective and reversible human BChE inhibitors were developed. The solved crystal structure of human BChE in complex with the most potent inhibitor reveals its binding mode and provides the molecular basis of its low nanomolar potency. Additionally, this compound is noncytotoxic and has neuroprotective properties. Furthermore, this inhibitor moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning abilities of mice in a model of the cholinergic deficit that characterizes AD, without producing acute cholinergic adverse effects. Our study provides an advanced lead compound for developing drugs for alleviating symptoms caused by cholinergic hypofunction in advanced AD.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
Tytuł:
8-hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases
Autorzy:
Sałat, Kinga
Skrzypczak-Wiercioch, Anna
Fernández, Ana Patricia
Stojan, Jure
Nachon, Florian
Knez, Damijan
Pišlar, Anja
Chioua, Mourad
Diez-Iriepa, Daniel
Binda, Claudia
Serrano, Julia
Sánchez-García, Aitana
Marco-Contelles, José
López-Munoz, Francisco
Meden, Anže
Denic, Milica
Gottinger, Andrea
Brazzolotto, Xavier
Gobec, Stanislav
Kos, Janko
Martínez-Murillo, Ricardo
Žakelj, Simon
Chantegreil, Fabien
Opis:
We describe the development of quinolylnitrones (QNs) as multifunctional ligands inhibiting cholinesterases (ChEs: acetylcholinesterase and butyrylcholinesteraseehBChE) and monoamine oxidases (hMAO-A/B) for the therapy of neurodegenerative diseases. We identified QN 19, a simple, low molecular weight nitrone, that is readily synthesized from commercially available 8-hydroxyquinoline-2-carbaldehyde. Quinolylnitrone 19 has no typical pharmacophoric element to suggest ChE or MAO inhibition, yet unexpectedly showed potent inhibition of hBChE (IC50 Z 1.06 0.31 nmol/L) and hMAO-B (IC50 Z 4.46 0.18 mmol/L). The crystal structures of 19 with hBChE and hMAO-B provided the structural basis for potent binding, which was further studied by enzyme kinetics. Compound 19 acted as a free radical scavenger and biometal chelator, crossed the bloodebrain barrier, was not cytotoxic, and showed neuroprotective properties in a 6-hydroxydopamine cell model of Parkinson’s disease. In addition, in vivo studies showed the anti-amnesic effect of 19 in the scopolamine-induced mouse model of AD without adverse effects on motoric function and coordination. Importantly, chronic treatment of double transgenic APPswe-PS1dE9 mice with 19 reduced amyloid plaque load in the hippocampus and cortex of female mice, underscoring the disease-modifying effect of QN 19.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł
    Wyświetlanie 1-9 z 9

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies